Printer Friendly

FUTURE MEDICAL PRODUCTS, INCORPORATED TO CONCENTRATE ON COMMERCIALIZATION OF CERTAIN PRODUCTS

 HAUPPAUGE, N.Y., Jan 5 /PRNewswire/ -- Future Medical Products, Inc. (NASDAQ: FMPI) announced today that it has revised its business strategy to concentrate all of its efforts in 1994 in three areas: the commercialization of its device for non-invasive angina treatment (EECP), pursuing joint venture and licensing agreements for the commercialization overseas of its butylurea compound with respect to an anti-HIV blood bag and other possible applications including and anti- HIV product for female contraception, and augmenting sales of its monoclonal antibodies and rapid diagnostic test kits.
 During the first half of 1994, the Company will be focusing its attention on the EECP, the product which it believes has the greatest potential to produce substantial revenues in 1994. Negotiations are currently under way for multiple sites, both domestic and foreign, for the use of the EECP for the non-invasive treatment of cardiac patients suffering from angina. This commercialization process will include educational and marketing programs directed at the medical community and the general public.
 In deciding to concentrate its efforts in this matter, the Company has divested its interest in its Vaso Diagnostic subsidiary and, as previously reported, has deferred indefinitely any additional clinical studies on its neuro-stimulator device (NSD). Its Vaso Diagnostic subsidiary, which performed non-invasive cardiac monitoring services for patients in New York and Connecticut, faced and unclear future due to the pending health bill and the related uncertainty of insurance reimbursement schedules. The Company sold this subsidiary back to its original owner and received $100,000 in excess of its investment.
 Future Medical Products, Inc. is a medical technology company involved in the research, development and distribution of innovative and cost effective health care products and processes.
 -0- 1/5/94
 /CONTACT: Thomas M. Dean, 212-421-2543, or Luis J. Mejia, 212-421-2543, both of Innovative Research Associates/
 (FMPI)


CO: Future Medical Products, Inc. ST: New York IN: MTC SU: PDT

MP-SP -- NY041 -- 9355 01/05/94 12:48 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 5, 1994
Words:321
Previous Article:RAYTHEON WINS $219 MILLION AIR FORCE MISSILE CONTRACT
Next Article:DAVID J. SMITH NAMED CFO OF THE TURNER CORPORATION
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters